SCHEMBL944176

SCHEMBL944176

O=C(O)c1nc(O)cc(O)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.39
TSHR P16473 2/20 0.39
HIF1A Q16665 1/20 0.39
CA12 O43570 3/20 0.36
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA7 P43166 3/20 0.36
CA9 Q16790 3/20 0.36
CA14 Q9ULX7 3/20 0.36
ALDH1A1 P00352 6/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
MAPK1 P28482 2/20 0.35
KDM4E B2RXH2 6/20 0.35
MAPT P10636 4/20 0.35
TDP1 Q9NUW8 2/20 0.35
CA4 P22748 2/20 0.35
CA6 P23280 2/20 0.35
ACMSD Q8TDX5 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1146219 0.75 TSHR (0.38) ALOX15TSHRHIF1ACA1CA2
Citrazinic Acid SCHEMBL185046 0.72 TSHR (0.56) ALOX15TSHRHIF1ACA12CA1
SCHEMBL3633436 0.72 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2MAPK1KDM4EMAPT
SCHEMBL8847206 0.72 ALOX15 (0.56) ALOX15TSHRHIF1AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL2032392 0.72 TSHR (0.36) ALOX15TSHRHIF1AALDH1A1SMN1; SMN2
SCHEMBL29223372 0.72 TSHR (0.36) ALOX15TSHRHIF1AALDH1A1SMN1; SMN2
Potassium SCHEMBL30932480 0.72 TSHR (0.36) ALOX15TSHRHIF1AALDH1A1SMN1; SMN2
Oteracil SCHEMBL7697987 0.71 ALOX15 (0.32) ALOX15TSHRHIF1AKDM4ETDP1
SCHEMBL12914934 0.70 CDC7 (0.38) TDP1HPGDPOLBGAAL3MBTL1
SCHEMBL163540 0.70 KMO (0.50) ALDH1A1KDM4EMAPTKDM6BTET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112547123-B Ir catalyst, preparation method and application thereof, and method for preparing hydrogen by using Ir catalyst 中国科学院苏州纳米技术与纳米仿生研究所 2023-05-26 CN disclosed
CN-112547123-A Ir catalyst, preparation method and application thereof, and method for preparing hydrogen by using Ir catalyst 中国科学院苏州纳米技术与纳米仿生研究所 2021-03-26 CN disclosed
US-20110009437-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-01-13 US disclosed
US-20110009437-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-01-13 US disclosed
US-20110009437-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-01-13 US disclosed
EP-2245025-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2010-11-03 EP disclosed
WO-2009106209-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009437-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES GLS, GCKR, HK1 ALOX15 1060/4885TSHR 1227/4885HIF1A 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.